Esperion to Participate in Upcoming BTIG Biotech Conference

ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET.

Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc.

Esperion Contact Information:
Investors:
Alina Venezia
[email protected]
(734) 887-3903

Media:
Tiffany Aldrich
[email protected]
(616) 443-8438

You May Also Be Interested In

• Everbright Digital Holding Limited Announces Pricing of $8.07 Million Public Offering
• Generation Uranium Announces Final CSE Listing Approval and Voluntary Delisting From the TSXV
• Rotoris Premieres The Rotoris Room in New York; Debuts a Global Conversation on Modern Masculinity Ahead of July 30 Release